Last reviewed · How we verify
Valchlor (MECHLORETHAMINE)
Valchlor (generic name: MECHLORETHAMINE) is a Alkylating Drug [EPC] Small molecule drug developed by Recordati. It is currently FDA-approved (first approved 1949) for Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma. Also known as: chlormethine.
Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.
Valchlor is a medication used in the treatment of certain types of cancer, including breast cancer, large granular lymphocytes leukemia, adult rhabdomyosarcoma, and childhood alveolar rhabdomyosarcoma. It is administered as part of a combination therapy with other medications, such as bevacizumab, doxorubicin, and cyclophosphamide.
At a glance
| Generic name | MECHLORETHAMINE |
|---|---|
| Also known as | chlormethine |
| Sponsor | Recordati |
| Drug class | Alkylating Drug [EPC] |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1949 |
Mechanism of action
Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.
Approved indications
- Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma
Common side effects
- Dermatitis
- Pruritus
- Bacterial skin infection
- Skin ulceration or blistering
- Skin hyperpigmentation
- Reductions in hemoglobin
- Neutrophil count reduction
- Platelet count reduction
- Discontinuations due to adverse reactions
- Temporary treatment suspension
- Reductions in dosing frequency
- Discontinuations for adverse reactions within the first 90 days
Drug interactions
- None
Key clinical trials
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant (PHASE1)
- Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC (PHASE1,PHASE2)
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (PHASE3)
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (PHASE1)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (PHASE1)
- TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis (EARLY_PHASE1)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Valchlor CI brief — competitive landscape report
- Valchlor updates RSS · CI watch RSS
- Recordati portfolio CI
Frequently asked questions about Valchlor
What is Valchlor?
How does Valchlor work?
What is Valchlor used for?
Who makes Valchlor?
What is the generic name of Valchlor?
Is Valchlor also known as anything else?
What drug class is Valchlor in?
When was Valchlor approved?
What development phase is Valchlor in?
What are the side effects of Valchlor?
Related
- Drug class: All Alkylating Drug [EPC] drugs
- Manufacturer: Recordati — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma
- Also known as: chlormethine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing